阿斯利康心脏病药物临床试验失败 伦敦股价暴跌9%AstraZeneca Shares Plummet 9% After Heart Drug Trial Fails

根据阿斯利康于周四早些时候发布的官方新闻稿，该公司对其心脏病药物Wainua进行的一项后期临床试验未能达到其预设的主要目标。在这项长达140周的临床研究中，研究人员对该药物的疗效进行了系统性评估。然而，最终的试验数据表明，与使用安慰剂的对照组相比，Wainua在减少患者心血管死亡人数以及降低复发性心脏相关紧急情况发生率这两个关键指标上，均未能展现出符合预期的显著临床效果。

According to an official press release issued by AstraZeneca early Thursday, the late-stage clinical trial for its heart disease drug, Wainua, failed to achieve its pre-specified primary objective. Over the course of the 140-week study, researchers evaluated the efficacy of the treatment against a placebo. The clinical data revealed that the drug did not meet its main goal of reducing cardiovascular-related deaths and decreasing the frequency of recurrent heart-related emergencies among the participating patients.

该项研究主要针对一种特定类型的罕见心脏疾病，其病理特征为折叠错误的蛋白质在患者的心肌中异常积聚。尽管阿斯利康对该药物在临床试验中的表现寄予厚望，但此次后期试验的最终结果未能满足其设定的主要终点要求，这也直接导致了该药物在后续针对该适应症的研发与应用上面临新的不确定性。

The clinical study specifically examined a form of the rare heart condition characterized by the accumulation of misfolded proteins within the heart muscle. Despite the British drugmaker's efforts to advance this treatment, the failure to reach the primary endpoint in this late-stage trial represents a significant setback for the clinical development of Wainua for this specific patient population.

在阿斯利康公布其心脏病药物Wainua后期临床试验未达主要终点的消息后，金融市场迅速做出反应。周四，这家英国制药巨头在伦敦证券交易所上市的股票价格遭遇重挫，盘中一度暴跌达9%。随后，该股股价小幅回升，但仍维持在下跌8.9%左右的低位水平。

Financial markets reacted swiftly to the announcement that AstraZeneca's late-stage clinical trial for its heart disease drug, Wainua, failed to meet its primary objective. On Thursday, shares of the British pharmaceutical giant plummeted on the London Stock Exchange, diving by as much as 9% during early trading. The stock was last seen down by approximately 8.9% as the market digested the disappointing clinical results.

此次股价大幅下跌使阿斯利康面临沉重的抛售压力。根据市场历史数据记录，这一单日跌幅创下了自2020年3月新冠疫情爆发初期以来，该公司股票在伦敦交易市场表现最差的一天。投资者的担忧情绪直接反映在股价的剧烈波动中，抹去了该股近期的部分涨幅。

This sharp decline in share price triggered significant selling pressure, putting the company's stock on track for its worst single-day trading performance in years. Market data indicates that this drop represents AstraZeneca's worst trading day in London since March 2020, which marked the turbulent start of the global Covid-19 pandemic.

转甲状腺素蛋白淀粉样变性心肌病（ATTR-CM）是一种罕见且危及生命的心脏疾病，目前估计全球约有50万人正遭受该病症的折磨。这种疾病的病理机制非常复杂，主要表现为折叠错误的蛋白质在患者的心肌组织中发生异常积聚。随着这些异常蛋白质的不断累积，心肌的正常结构和生理功能会受到严重损害，从而导致患者的心脏功能逐渐衰竭并危及生命。

Transthyretin-mediated amyloid cardiomyopathy, commonly known as ATTR-CM, is a rare and life-threatening heart condition that is estimated to affect approximately half a million people worldwide. The disease is characterized by a specific pathological process in which misfolded proteins abnormally build up within the heart muscle. Over time, this protein accumulation severely compromises the structural integrity and pumping efficiency of the heart, leading to progressive cardiac dysfunction and a high risk of mortality.

阿斯利康研发的Wainua正是针对这一特定病理机制而设计的治疗药物。该项临床研究专门针对这种因折叠错误蛋白质积聚而引起的心肌病变类型进行了深入探索。由于该疾病在临床上面临着极高的致死风险且缺乏有效的治疗选择，因此针对该靶点的药物研发一直受到医学界和患者群体的密切关注。

AstraZeneca's drug Wainua was specifically designed to target this underlying mechanism by addressing the accumulation of these misfolded proteins in the heart muscle. Because of the severe and life-threatening nature of ATTR-CM, as well as the limited treatment options currently available to patients, clinical research in this area remains highly critical for the global medical community.

杰富瑞（Jefferies）分析师对临床试验结果进行了评估。该机构分析师指出，尽管阿斯利康此前对Wainua的主要终点以及在联合用药中的疗效表现出了极高的信心，但后期临床试验的失败并不会动摇该公司长期财务规划的根基。分析师强调，这一挫折并不会危及阿斯利康此前设定的到2030年实现800亿美元销售额的目标。

An analyst from Jefferies evaluated the clinical trial results, noting that while AstraZeneca had previously expressed high confidence in Wainua's primary endpoint and its efficacy in combination use, the late-stage trial failure does not undermine the company's long-term financial foundations. The analyst emphasized that this clinical setback does not jeopardize AstraZeneca's ambitious target of achieving $80 billion in sales by the year 2030.

尽管该药物未能在减少心血管死亡和紧急情况方面取得预期成果，但分析师的评估表明，阿斯利康多元化的产品管线和整体业务布局依然稳固。虽然市场在短期内对试验失败做出了剧烈反应，导致股价大幅下跌，但从长期来看，该公司实现其2030年销售目标的整体路径并未受到颠覆。

Despite the drug's inability to deliver the expected reductions in cardiovascular deaths and emergencies, the analyst's assessment suggests that AstraZeneca's diversified pipeline and broader business portfolio remain resilient. While the market reacted sharply in the short term with a significant drop in share price, the company's overall trajectory toward its 2030 revenue goals is not fundamentally disrupted by this single clinical trial outcome.